Tumor Markers for NEET PG: The Complete List and What They Actually Mean
Reflex · 4 Jun 2026 · 2 min read
On this page
Tumor marker questions are some of the most reliably one-to-one in Pathology — a marker, a cancer, done. The trap isn’t the matching; it’s assuming these markers are used for screening the way people assume, when most of them are really monitoring tools.
The High-Yield List
| Marker | Associated cancer |
|---|---|
| AFP (alpha-fetoprotein) | Hepatocellular carcinoma; yolk sac (endodermal sinus) tumor; non-seminomatous germ cell tumors |
| CEA (carcinoembryonic antigen) | Colorectal cancer (also raised in pancreatic, gastric, breast cancer — nonspecific) |
| CA-125 | Epithelial ovarian cancer |
| CA 19-9 | Pancreatic cancer |
| PSA (prostate-specific antigen) | Prostate cancer |
| β-hCG | Choriocarcinoma, germ cell tumors, hydatidiform mole |
| CA 15-3 | Breast cancer |
| NSE (neuron-specific enolase) | Small cell lung carcinoma, neuroblastoma |
| S-100 | Melanoma, neural tumors, Langerhans cell histiocytosis |
| Alkaline phosphatase | Bone metastases, Paget’s disease, osteosarcoma |
| Chromogranin A | Neuroendocrine tumors |
The Distinction Examiners Actually Test
Most tumor markers lack the sensitivity and specificity to be useful screening tools in an asymptomatic population — they’re elevated by plenty of benign conditions too (CA-125 rises in endometriosis and even menstruation; CEA rises in smokers and inflammatory bowel disease). Where they earn their place clinically is in monitoring: tracking a marker after treatment to catch recurrence early, or watching it trend down to confirm treatment response.
PSA is the frequent exception raised in screening discussions, but even there, current practice treats population-wide screening as a nuanced, patient-specific decision rather than a blanket recommendation — a detail worth remembering if a question frames PSA as a universal screening tool.
A Few Pairings Worth Double-Checking
- AFP is elevated in hepatocellular carcinoma and yolk sac tumors, but not in pure seminoma — a classic distractor, since seminomas can still show mild β-hCG elevation.
- CA 19-9 is the go-to for pancreatic cancer, but it’s also elevated in cholangiocarcinoma and benign biliary obstruction, so it isn’t purely cancer-specific either.
- Alkaline phosphatase rising with bone metastases is a liver-independent clue — pair it with a normal GGT to confirm the source is bone rather than liver.
Matching questions like this reward speed and accuracy under time pressure — exactly the format Reflex’s daily TROCAR Pathology rounds are built around.
Practise this on Reflex
Turn what you just read into recall with 14 years of tagged PYQs.
FAQ
Frequently asked questions
The questions aspirants ask most about this topic.
CA-125, though it’s used more for monitoring treatment response than for standalone screening due to its low specificity.
AFP (alpha-fetoprotein).
Rarely as standalone screening tools — most lack the specificity needed, since benign conditions can also raise them. Their main clinical value is monitoring treatment response and detecting recurrence.
CA 19-9.
Stay ahead in your preparation
Get expert tips, exam updates, and high-yield insights delivered straight to your inbox.
No spam. Unsubscribe anytime.
